1 citations
,
May 2023 in “Journal of the American Academy of Dermatology” In this retrospective study, 75% of patients with alopecia areata responded well to an 8-week oral methylprednisolone tapering treatment, but 28.4% relapsed within an average of 5.5 months; young age and extensive alopecia predicted poorer responses, and low vitamin D was linked to relapse.
19 citations
,
May 2009 in “Pediatric Dermatology” This case report describes a 5-year-old girl with childhood discoid lupus erythematosus, where treatment led to reversal of scarring alopecia and hair regrowth.
4 citations
,
January 2019 in “Open Access Macedonian Journal of Medical Sciences” In this study, oral mini-pulse methylprednisolone therapy for alopecia areata was reported to be effective and safe over 6 months, with 82.2% of patients recovering well and no adverse events observed.
September 2025 in “Tạp chí Da liễu học Việt Nam” In this study, combining ablative fractional microneedle radiofrequency with oral methylprednisolone was found to enhance hair density and mature hair rates in patients with alopecia areata better than oral methylprednisolone alone, though some adverse effects and increased hair shedding were noted over time.
July 2013 in “Our Dermatology Online” In this case study, an 11-year-old boy with extensive alopecia areata showed 80% hair regrowth after six months of treatment with methylprednisolone despite initial lack of response to topical therapies.